Immunotherapy News and Research

Latest Immunotherapy News and Research

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma.

18 Aug 2015

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT).

17 Aug 2015

Centenary Institute researchers take lead on promising new class of drugs for melanoma treatment

Researchers at Sydney’s Centenary Institute have taken the lead on a promising new class of drugs that may prove to be highly effective for the treatment of certain cases of melanoma.

14 Aug 2015

ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

ImmunoCellular Therapeutics, Ltd. announced today that it has reached agreement with the US Food and Drug Administration on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer immunotherapy ICT-107 to treat patients with newly diagnosed glioblastoma.

13 Aug 2015

Janssen signs license agreement with Alligator Bioscience for immuno-oncology antibody

Janssen Biotech, Inc., one of the Janssen pharmaceutical companies of Johnson & Johnson announced today an exclusive, worldwide license agreement with Alligator Bioscience AB for ADC-1013, an immuno-oncology agent currently in Phase 1 clinical studies.

12 Aug 2015

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy in patients with localized renal cell carcinoma.

11 Aug 2015

Sorrento, TNK Therapeutics to exclusively license NanoVelcro CTC assay from CytoLumina and FetoLumina

Sorrento Therapeutics, Inc. announced today that it as well as its wholly-owned subsidiary TNK Therapeutics, Inc. have entered into a binding term sheet to exclusively license the NanoVelcro Circulating Tumor Cell (CTC) profiling assay technology from CytoLumina Technologies Corp. and FetoLumina Technologies Corp., two privately-held sister biotechnology companies in Los Angeles, California.

11 Aug 2015

Researchers create new cell screening method for immunotherapy cancer treatments

Researchers have created a new method for screening cells used in immunotherapy cancer treatments, allowing high-performing immune system cells to be studied in isolation and potentially expanding the number of patients for whom the breakthrough treatment proves successful.

11 Aug 2015

CRI to honor three scientists for contributions to immunology and cancer immunotherapy research

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, will bestow its highest honors on three scientists who have made fundamental contributions to the fields of immunology and cancer immunotherapy.

10 Aug 2015

CRI announces winners of 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced today the winners of the 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research.

10 Aug 2015

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

Sorrento Therapeutics, Inc. announced today that its wholly-owned subsidiary, TNK Therapeutics, Inc., has acquired multiple preclinical and clinical stage chimeric antigen receptor (CAR)-T immunotherapy programs as well as underlying CAR-T technology through the acquisition of two privately-held biotechnology companies.

10 Aug 2015

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

Mallinckrodt plc, a leading specialty biopharmaceutical company, and The Gores Group, a global investment firm, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Therakos, Inc. a leading immunotherapy company in a transaction valued at approximately $1.325 billion.

10 Aug 2015

Experts discuss ways to encourage appropriate use of epinephrine for all severe allergic reactions

There are times when emergency physicians can't be 100 percent sure a person is suffering from a severe allergic reaction, known as anaphylaxis, and may hesitate to use epinephrine. A new article says when in doubt - administer the epinephrine.

7 Aug 2015

Researcher reveals link between inflammatory response of neutrophils and spread of oral cancer

An abnormal immune response or "feedback loop" could very well be the underlying cause of metastases in oral cancers, according to Dr. Marco Magalhaes, Assistant Professor at the University of Toronto's Faculty of Dentistry and lead researcher in a study published in the journal Cancer Immunology Research.

7 Aug 2015

Celsion reports updated results from HEAT Study of ThermoDox in patients with primary liver cancer

Celsion Corporation, an oncology drug development company, today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC).

6 Aug 2015

Heptares, AstraZeneca sign licensing agreement to develop and commercialise immuno-oncology treatments

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.

6 Aug 2015

WI Harper Group announces investment in Cold Genesys

WI Harper Group, a leading US & China, cross-border early growth and expansion stage venture capital firm, today announced an investment in Cold Genesys Inc, a clinical-stage privately-held biotech company developing oncolytic immunotherapies for cancer.

6 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Top cancer research organizations to sponsor International Cancer Immunotherapy Conference in New York

The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept. 16-19, 2015.

4 Aug 2015

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Sorrento Therapeutics, Inc. announced today that it has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China.

3 Aug 2015

Immunotherapy News and Research

Latest Immunotherapy News and Research

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Centenary Institute researchers take lead on promising new class of drugs for melanoma treatment

ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

Janssen signs license agreement with Alligator Bioscience for immuno-oncology antibody

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Sorrento, TNK Therapeutics to exclusively license NanoVelcro CTC assay from CytoLumina and FetoLumina

Researchers create new cell screening method for immunotherapy cancer treatments

CRI to honor three scientists for contributions to immunology and cancer immunotherapy research

CRI announces winners of 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

Experts discuss ways to encourage appropriate use of epinephrine for all severe allergic reactions

Researcher reveals link between inflammatory response of neutrophils and spread of oral cancer

Celsion reports updated results from HEAT Study of ThermoDox in patients with primary liver cancer

Heptares, AstraZeneca sign licensing agreement to develop and commercialise immuno-oncology treatments

WI Harper Group announces investment in Cold Genesys

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Top cancer research organizations to sponsor International Cancer Immunotherapy Conference in New York

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Immunotherapy News and Research

Latest Immunotherapy News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in